Voices
Justin Stebbing
Justin Stebbing/healthpost.in

Justin Stebbing: The Ability of Botensilimab/Balstilimab to Induce Durable Responses in ‘Cold Tumours’

Justin Stebbing, Editor-in-Chief of Oncogene and Consultant Oncologist at London Lauriston Clinic, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:

“The ability of bot/bal Immunotherapy to Induce Durable Responses in ‘cold tumours’ is really impressive, and am super lucky to be part of the team here.”

Title: Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer

Authors: Rebecca Porter, Bruno Bockorny, Bradley R. Corr, Daruka Mahadevan, Breelyn A. Wilky, Anthony B. El-Khoueiry, Andrea J. Bullock, Navid Hafez, Justin Moser, Anastasia Martynova, Justin Stebbing, Bishnu Joshi, Sean Bourdelais, Chloe Delepine, Dhan Chand, Wei Wu, Benny Johnson, Joseph E. Grossman, Steven J. O’Day, Ursula A. Matulonis, Michael S. Gordon

Read the Full Article on The Journal for ImmunoTherapy of Cancer

Justin Stebbing: The Ability of Botensilimab/Balstilimab to Induce Durable Responses in 'Cold Tumours'

You can also read: Botensilimab + Balstilimab in Platinum-Resistant Ovarian Cancer

ovarian cancer

 

Anastasia Martynova Andrea J. Bullock Anthony B. El-Khoueiry Benny Johnson Bishnu Joshi Bradley R. Corr Breelyn A. Wilky Bruno Bockorny cancer Chloe Delepine Daruka Mahadevan Dhan Chand immunotherapy Joseph E. Grossman Justin Moser Justin Stebbing Michael S. Gordon Navid Hafez OncoDaily Oncology Ovarian Cancer Rebecca Porter Sean Bourdelais Steven J. O’Day Ursula A. Matulonis Wei Wu